Abstract

Mesenchymal condensation is a critical step in organogenesis, yet the underlying molecular and cellular mechanisms remain poorly understood. The hair follicle dermal condensate is the precursor to the permanent mesenchymal unit of the hair follicle, the dermal papilla, which regulates hair cycling throughout life and bears hair inductive potential. Dermal condensate morphogenesis depends on epithelial Fibroblast Growth Factor 20 (Fgf20). Here, we combine mouse models with 3D and 4D microscopy to demonstrate that dermal condensates form de novo and via directional migration. We identify cell cycle exit and cell shape changes as early hallmarks of dermal condensate morphogenesis and find that Fgf20 primes these cellular behaviors and enhances cell motility and condensation. RNAseq profiling of immediate Fgf20 targets revealed induction of a subset of dermal condensate marker genes. Collectively, these data indicate that dermal condensation occurs via directed cell movement and that Fgf20 orchestrates the early cellular and molecular events.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE110459. All data analyzed for this study are included in the manuscript and supporting files. Source data files have been provided where appropriate.

The following data sets were generated

Article and author information

Author details

  1. Leah C Biggs

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    For correspondence
    leah.biggs@helsinki.fi
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4990-8664
  2. Otto J.M. Mäkelä

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6852-9814
  3. Satu-Marja Myllymäki

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  4. Rishi Das Roy

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  5. Katja Närhi

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  6. Johanna Pispa

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  7. Tuija Mustonen

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2429-5064
  8. Marja L Mikkola

    Developmental Biology Program, University of Helsinki, Helsinki, Finland
    For correspondence
    marja.mikkola@helsinki.fi
    Competing interests
    The authors declare that no competing interests exist.

Funding

Sigrid Juséliuksen Säätiö

  • Marja L Mikkola

Jane and Aatos Erkko Foundation

  • Marja L Mikkola

Doctoral Program in Integrative Life Science of the University of Helsinki

  • Otto J.M. Mäkelä

Academy of Finland (268798)

  • Marja L Mikkola

Academy of Finland (307421)

  • Marja L Mikkola

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mouse studies were approved and carried out in accordance with the guidelines of the Finnish national animal experimentation board under licenses KEK16-021 and ESAV/2363/04.10.07/2017.

Copyright

© 2018, Biggs et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,376
    views
  • 546
    downloads
  • 84
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Leah C Biggs
  2. Otto J.M. Mäkelä
  3. Satu-Marja Myllymäki
  4. Rishi Das Roy
  5. Katja Närhi
  6. Johanna Pispa
  7. Tuija Mustonen
  8. Marja L Mikkola
(2018)
Hair follicle dermal condensation forms via Fgf20 primed cell cycle exit, cell motility, and aggregation
eLife 7:e36468.
https://doi.org/10.7554/eLife.36468

Share this article

https://doi.org/10.7554/eLife.36468

Further reading

    1. Cell Biology
    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.

    1. Cell Biology
    2. Developmental Biology
    Sarah Y Coomson, Salil A Lachke
    Insight

    A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.